Nanobiotix has appointed Dr. Bernd Muehlenweg, currently Head of Business Development, as a member of the Executive Board in support of the future growth of Nanobiotix.

Bernd Muehlenweg joined Nanobiotix in 2011 as Head of Business Development. From 2001 to 2011, he had been Director Business Development of oncology company WILEX AG (Munich, Germany), where he played a key role in the negotiation and execution of several license and commercialization agreements with pharma companies and in alliance management. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Pharma Licensing Club of France.

As every year, akampion will attend some key industry events and conferences. Moreover, we are very happy to contribute to the organization and preparation of two of these events: DVFA Life Science Conference and Deutsche Biotechnologietage (German Biotechnology Industry Event).

Our team will be available at the following conferences in April and May:

• Charité Summit, April 23-24 (Berlin)
• DVFA Life Science Conference, May 8 (Frankfurt)
• Deutsche Biotechnologietage, May 9-10 (Frankfurt)
• Bio€quity, May 15-16 (Frankfurt)

We are looking forward to meeting you and hope to share latest industry insights and thoughts!

- InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer -

Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions to its management team: Pernilla Sandwall has been appointed as Head of Clinical Operations and Thomas Knittel as Chief Medical Officer. Pernilla Sandwall will lead the company’s clinical development team, with the main focus being the ongoing phase III clinical trial of Kappaproct^® in patients with treatment-refractory ulcerative colitis. Thomas Knittel will serve as the company’s lead medical expert and provide leadership in medical and marketing affairs.  » Read more...

- Lead investor Banexi Ventures Partners joins strong investment consortium -

Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series B financing round totaling CHF 4.0 million.

Banexi Ventures Partners acted as a lead investor in the financing, with selected private investors also participating in the round. Existing institutional investors are BioMedInvest AG, BB BIOTECH VENTURES III, L.P. and Initiative Capital Romandie.

The proceeds will be used to advance Aleva’s leading-edge neurostimulation products through clinical development up to CE marking. Aleva´s products are based on its proprietary, next-generation microDBS™ technology for Deep Brain Stimulation therapy (DBS).  » Read more...

- Demonstration supported by symposium on bacterial pneumonia and emerging antibiotic resistance at the 22^nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) -

Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced the presentation of its Unyvero™ System and the Unyvero™ P50 Pneumonia Cartridge during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London.

The showcasing will be accompanied by the Curetis-sponsored Integrated Symposium “Bacterial Pneumonia and Emerging Antibiotic Resistance”, which will focus on pneumonia-causing pathogens, their respective antibiotic resistances, and the relevance of multiplexed molecular diagnostic testing. The event will be chaired by clinical microbiologist and molecular diagnostics specialist Prof. Christine Ginocchio (North Shore-LIJ Health System School of Medicine, New York), and Prof. Keith Klugman (Emory University, Atlanta), the world’s premier expert on antibiotic resistance among pneumococcal bacteria.  » Read more...